|
|
|
| Medical Degree: |
M.D., Universidad de Barcelona, 1990
|
|---|
| Fellowship: |
Hematology/Oncology, UCLA School of Medicine, 2001
Surgical Oncology, UCLA School of Medicine, 1998
|
|---|
| Medical Experience: |
Residency, Hospital Vall d'Hebron, 1994
|
|---|
| Internship: |
Medical Oncology, Hospital Vall d'Hebron, 1991
|
|---|
|
|
|
| Work Address: |
11-934 Factor
Campus - 167817
CA
UNITED STATES
|
|---|
|
Dr. Ribas is an Associate Professor with a double appointment in Medicine (Hematology-Oncology) and Surgery (Surgical Oncology). He is Assistant Director for Clinical Programs, UCLA Human Gene Medicine Program, Director, JCCC Cell and Gene Therapy Core Facility, General Clinical Research Center Advisory Board Member and Faculty Advisor to the UCLA Residency Program. Dr. Ribas trained at the University of Barcelona, Spain, and has undergone postdoctoral training at the Sidney Kimmel Cancer Center in San Diego and at UCLA. He joined the UCLA Hematology-Oncology Fellowship program and is a faculty member since July of 2001.
Dr. Ribas and his colleagues are conducting studies aimed at understanding how the immune system can be effectively used to treat cancer. The work is focused on the ability to activate killer immune cells specifically targeted to the cancer. One line of research is the use of dendritic cells engineered to express tumor antigens, which have been shown to induce powerful responses against cancer. This approach has been taken from preclinical studies in mice to a phase I clinical trial for the treatment of patients with malignant melanoma. Assays with defined performance specifications determined in detailed methodology studies are being used for the immune monitoring of the human clinical trials. Another line of research is the stimulation of innate responses to tumors. Dendritic cells are very powerful in activating natural killer cells that lead to tumor regressions, and the immunobiology of these responses are being studied. Additional interests of the laboratory are the use of interventions that modify the regulation of tumor-specific lymphocytes, and the pharmacological modulation of the interaction between the lytic immune cells (cytotoxic T lymphocytes or natural killer cells) with the cancer cells, with the goal of further increasing their antitumor potential.
|
|
|
|
Schumacher L, Ribas A, Dissette VB, McBride WH, Mukherji B, Economou JS, Butterfield LH Human dendritic cell maturation by adenovirus transduction enhances tumor antigen-specific T-cell responses..
Journal of immunotherapy (Hagerstown, Md. : 1997) .
2004; 27(3):
191-200.
Ribas A, Glaspy JA, Lee Y, Dissette VB, Seja E, Vu HT, Tchekmedyian NS, Oseguera D, Comin-Anduix B, Wargo JA, Amarnani SN, McBride WH, Economou JS, Butterfield LH Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy..
Journal of immunotherapy (Hagerstown, Md. : 1997) .
2004; 27(5):
354-67.
Liao YP, Wang CC, Butterfield LH, Economou JS, Ribas A, Meng WS, Iwamoto KS, McBride WH Ionizing radiation affects human MART-1 melanoma antigen processing and presentation by dendritic cells..
Journal of immunology (Baltimore, Md. : 1950) .
2004; 173(4):
2462-9.
Gordon LK, Ribas A, Nusinowitz S, Butterfield LH, Glaspy JA, Economou JS, Straatsma BR Surveillance of the eye and vision in a clinical trial of MART1-transformed dendritic cells for metastatic melanoma..
Controlled clinical trials. .
2004; 25(4):
400-7.
Ribas A, Wargo JA, Comin-Anduix B, Sanetti S, Schumacher LY, McLean C, Dissette VB, Glaspy JA, McBride WH, Butterfield LH, Economou JS Enhanced tumor responses to dendritic cells in the absence of CD8-positive cells..
Journal of immunology (Baltimore, Md. : 1950) .
2004; 172(8):
4762-9.
|
|
|
|
Disability Resources
